Upcoming patent expirations, lagging pipelines and a tough regulatory climate prompted Moody's Investors Services to downgrade its credit ratings outlook for the pharmaceutical industry on Wednesday.
In a research report, Moody's senior vice president and credit analyst Michael Levesque cut his 12-month outlook to "Negative" from "Stable."
More
No comments:
Post a Comment